Juvenile Idiopathic Arthritis (JIA)

1. Clinical Overview

Summary

Juvenile Idiopathic Arthritis (JIA) is the most common chronic rheumatic disease of childhood, encompassing a heterogeneous group of conditions unified by the presence of arthritis persisting for ≥6 weeks in a child less than 16 years of age, with no identifiable cause. [1] The International League of Associations for Rheumatology (ILAR) classification divides JIA into seven distinct categories: oligoarticular, polyarticular rheumatoid factor (RF)-negative, polyarticular RF-positive, systemic, enthesitis-related arthritis (ERA), psoriatic arthritis, and undifferentiated arthritis. [2]

JIA affects approximately 1 in 1,000 children and represents a major cause of chronic disability in the paediatric population. [1] The condition is characterised by chronic synovial inflammation leading to joint pain, swelling, stiffness, and potential long-term sequelae including joint damage, growth impairment, and functional disability. [1,3]

A critical and potentially sight-threatening complication is chronic anterior uveitis, which occurs most frequently in young girls with oligoarticular JIA who are antinuclear antibody (ANA)-positive. [4] This inflammatory eye condition is typically asymptomatic in early stages, necessitating regular ophthalmological screening with slit-lamp examination to prevent irreversible vision loss from complications such as posterior synechiae, band keratopathy, cataract, glaucoma, and phthisis bulbi. [4]

The therapeutic landscape for JIA has been revolutionised over the past two decades with the introduction of biologic disease-modifying antirheumatic drugs (DMARDs), particularly tumour necrosis factor (TNF) inhibitors, interleukin-1 (IL-1) antagonists, and interleukin-6 (IL-6) receptor blockers. [5,6] Modern treatment strategies emphasise early aggressive therapy to achieve inactive disease and prevent long-term complications, with the majority of patients now able to achieve remission or low disease activity. [5,7]

Key Facts

• Definition: Arthritis in child less than 16 years, persisting ≥6 weeks, with exclusion of other causes
• Incidence: Approximately 10-20 per 100,000 children per year [1]
• Prevalence: ~1 in 1,000 children [1]
• ILAR Classification: Seven categories with distinct clinical and prognostic features [2]
• Most Common Subtype: Oligoarticular JIA (40-50% of all JIA cases) [1]
• Systemic JIA: Characterised by quotidian (daily spiking) fever, evanescent rash, serositis [8]
• Uveitis Risk: Highest in ANA-positive oligoarticular JIA (up to 30% of patients) [4]
• Macrophage Activation Syndrome: Life-threatening complication in 10-20% of systemic JIA patients [9]
• Treatment Goals: Inactive disease, prevention of joint damage, normal growth, optimal quality of life [5]
• Remission Rates: 50-70% achieve remission or inactive disease with modern therapies [7]

Clinical Pearls

"The Silent Eye": Chronic anterior uveitis in JIA is asymptomatic in early stages. Regular slit-lamp screening is mandatory - not optional. ANA-positive oligoarticular JIA in young girls carries the highest risk (up to 30%). Screen every 3 months for high-risk patients. [4]

"Quotidian Fever = Systemic JIA": Daily high spiking fevers (often to 39-40°C) that return rapidly to baseline or below normal (quotidian pattern) are pathognomonic for systemic JIA. The fever often occurs in the evening and may be accompanied by an evanescent salmon-pink rash. [8]

"Oligo = Knees and Ankles": Oligoarticular JIA preferentially affects large joints, particularly knees and ankles. Look for leg length discrepancy from accelerated growth at the affected knee - a classic finding. [1]

"MAS is a Rheumatological Emergency": Macrophage Activation Syndrome complicating systemic JIA has 8-10% mortality. Suspect if persistent fever, falling platelet count, rising ferritin (often > 10,000 μg/L), hepatosplenomegaly, and coagulopathy develop. [9]

"Early Biologics Change Everything": Modern era JIA outcomes are dramatically better than historical data. Early use of methotrexate and biologics prevents joint damage and achieves inactive disease in the majority. Don't wait to escalate therapy. [5,7]

"TMJ Involvement is Underdiagnosed": Temporomandibular joint (TMJ) arthritis occurs in 30-40% of JIA patients but is often asymptomatic. Progressive micrognathia (small jaw) may be the only sign. MRI is more sensitive than clinical examination. [10]

"Morning Stiffness, Not Just Pain": Morning stiffness > 15 minutes (often 1-2 hours) is a cardinal feature of inflammatory arthritis. Young children may not complain but instead refuse to walk or have a "gelling" phenomenon after inactivity. [1]

---

2. Epidemiology

Incidence and Prevalence

Juvenile Idiopathic Arthritis is the most common chronic rheumatic condition in children, with an estimated prevalence of approximately 1 in 1,000 children (0.07-4.01 per 1,000 depending on geographic region and methodology). [1] Annual incidence ranges from 10-20 per 100,000 children, with significant variation across populations. [1]

Demographics by Subtype

The seven ILAR categories demonstrate distinct demographic patterns:

Oligoarticular JIA (40-50% of all JIA)

Polyarticular RF-Negative JIA (20-30% of all JIA)

Polyarticular RF-Positive JIA (5-10% of all JIA)

Systemic JIA (5-15% of all JIA)

Enthesitis-Related Arthritis (10-15% of all JIA, up to 20% in some populations)

Psoriatic Arthritis (5-10% of all JIA)

Undifferentiated Arthritis

Arthritis that does not fulfil criteria for any category or fulfils criteria for more than one category. [2]

Geographic and Ethnic Variation

• Higher prevalence: Northern European populations, North America
• Lower prevalence: Asian and African populations
• Subtype variation: Enthesitis-related arthritis more common in Asian populations; oligoarticular JIA more common in Caucasian populations [1]

---

3. Aetiology and Pathophysiology

Aetiology

Juvenile Idiopathic Arthritis is a multifactorial condition arising from complex interactions between genetic susceptibility, environmental triggers, and immune dysregulation. The term "idiopathic" reflects the fact that no single causative agent has been identified. [1]

Genetic Factors

• HLA Associations: Multiple human leukocyte antigen (HLA) alleles confer susceptibility:
  • "HLA-DRB1 (particularly *04 and *11 alleles): Associated with oligoarticular JIA and uveitis risk [1]"
  • "HLA-B27: Strong association with enthesitis-related arthritis (70-90% positive) [1]"
  • "HLA-A2: Associated with early-onset oligoarticular JIA [1]"
• Non-HLA Genes: PTPN22, STAT4, IL2RA, IL6R, and other immune-related genes identified through genome-wide association studies (GWAS) [1]
• Twin Studies: Concordance rates in monozygotic twins vary by subtype but are generally less than 25%, indicating significant environmental contribution [1]
• Family History: 10-15% of JIA patients have a first- or second-degree relative with autoimmune disease [1]

Environmental Factors

Proposed triggers (evidence limited and inconsistent):

• Infections: Possible molecular mimicry between microbial antigens and self-antigens
• Microbiome: Altered gut microbiota composition observed in some JIA subtypes
• Perinatal factors: Some studies suggest associations with maternal smoking, low birth weight
• No proven prevention strategy: Unlike some autoimmune conditions, no specific environmental intervention has been proven to prevent JIA onset

Pathophysiology

The pathophysiology of JIA varies significantly by subtype, reflecting the heterogeneity of the condition.

Oligoarticular and Polyarticular JIA: Adaptive Immune Response

Exam Detail: These subtypes are characterised by autoimmune inflammation driven primarily by adaptive immune mechanisms:

1. Synovial Inflammation

• Infiltration of CD4+ T cells (particularly Th1 and Th17 subsets) into synovial membrane
• B cell activation with production of autoantibodies (RF in polyarticular RF+; ANA in many oligoarticular cases)
• Macrophage activation and secretion of pro-inflammatory cytokines

2. Cytokine Cascade

• TNF-α: Central mediator of synovial inflammation and joint destruction
• IL-1: Promotes cartilage degradation and bone resorption
• IL-6: Drives acute-phase response, contributes to systemic symptoms
• IL-17: Produced by Th17 cells; promotes neutrophil recruitment and bone erosion

3. Joint Damage Mechanisms

• Pannus formation: Proliferative synovitis invades and destroys cartilage and bone
• Matrix metalloproteinases (MMPs): Degrade collagen and proteoglycans in cartilage
• Receptor activator of nuclear factor-κB ligand (RANKL): Stimulates osteoclast activity → bone erosion
• Angiogenesis: Vascular endothelial growth factor (VEGF) promotes neovascularisation of inflamed synovium

4. Uveitis Pathogenesis

• Mechanisms incompletely understood
• Likely represents ocular manifestation of same autoimmune process
• ANA positivity strongly associated with uveitis risk (mechanism unclear)
• Chronic anterior segment inflammation → posterior synechiae, band keratopathy, glaucoma

Systemic JIA: Autoinflammatory Mechanism

Exam Detail: Systemic JIA (sJIA) is now recognised as fundamentally different from other JIA subtypes, representing an autoinflammatory rather than autoimmune condition: [8]

1. Innate Immune Activation

• Dysregulated innate immune system with hyperactivation of monocytes, macrophages, and neutrophils
• NO characteristic autoantibodies (ANA and RF typically negative)
• Minimal adaptive immune involvement (in contrast to other JIA subtypes)

2. Cytokine Profile

• IL-1β: Central driver of systemic inflammation; responsible for fever and systemic features [8]
• IL-6: Markedly elevated; drives acute-phase response (ferritin, CRP, ESR) [8]
• IL-18: Elevated; associated with MAS risk
• TNF-α: Less central than in other JIA subtypes

3. Clinical Manifestations

• Quotidian fever: IL-1β-mediated hypothalamic effects
• Evanescent rash: Neutrophil-mediated dermal inflammation
• Serositis: Pericarditis, pleuritis from systemic inflammation
• Hepatosplenomegaly: Extramedullary haematopoiesis and reticuloendothelial activation

4. Macrophage Activation Syndrome (MAS)

• Life-threatening complication in 10-20% of sJIA patients [9]
• Represents secondary haemophagocytic lymphohistiocytosis (HLH)
• Pathogenesis: Excessive activation and proliferation of T lymphocytes and macrophages with haemophagocytosis
• Triggers: Infections, medication changes, disease flares
• 2016 Classification Criteria for MAS in sJIA: [9]
  • "Ferritin > 684 ng/mL PLUS any two of:"
    • Platelet count ≤181 × 10⁹/L
    • Aspartate aminotransferase > 48 U/L
    • Triglycerides > 156 mg/dL (1.76 mmol/L)
    • Fibrinogen ≤360 mg/dL (3.6 g/L)

Enthesitis-Related Arthritis: Spondyloarthropathy

ERA represents the paediatric manifestation of spondyloarthropathy:

• Strong HLA-B27 association (70-90% positive) [1]
• Inflammation at entheses (tendon/ligament insertion sites) in addition to synovitis
• Risk of sacroiliitis and progression to ankylosing spondylitis in adulthood
• Pathophysiology shares features with adult spondyloarthropathies

Growth Impairment Mechanisms

JIA can affect growth through multiple mechanisms:

Local Growth Disturbances

• Accelerated growth: Chronic inflammation → hyperaemia → increased blood flow to growth plates → limb overgrowth (e.g., leg length discrepancy from knee arthritis)
• Impaired growth: Severe/prolonged inflammation or joint damage → growth plate damage → limb shortening

Generalised Growth Impairment

• Systemic inflammation: Chronic elevation of IL-6, IL-1, TNF-α → suppression of growth hormone axis
• Glucocorticoid therapy: Dose and duration-dependent suppression of linear growth
• Malnutrition: Chronic disease → anorexia, increased metabolic demands → inadequate nutrition for growth

Micrognathia (Small Jaw)

• TMJ arthritis → impaired mandibular growth → retrognathia, micrognathia, malocclusion [10]

---

4. Clinical Presentation

ILAR Classification System

The International League of Associations for Rheumatology (ILAR) classification divides JIA into seven categories based on clinical and laboratory features during the first 6 months of disease. [2] This classification has important prognostic and therapeutic implications.

Exclusion Criteria (Apply to All Categories)

Before classifying JIA, the following conditions must be excluded:

• Infection-related arthritis (septic arthritis, Lyme disease, reactive arthritis)
• Inflammatory bowel disease-associated arthritis
• Malignancy (particularly acute leukaemia - arthralgia is a presenting feature in 25% of ALL)
• Systemic lupus erythematosus or other defined connective tissue disease
• Vasculitis
• Other defined arthritis conditions

Detailed Subtype Presentations

1. Oligoarticular JIA (40-50% of JIA)

Definition: Arthritis affecting 1-4 joints during the first 6 months of disease. [2]

Subdivisions:

• Persistent oligoarticular: Affects ≤4 joints throughout disease course
• Extended oligoarticular: Affects > 4 joints after the first 6 months

Clinical Features:

Laboratory Features:

• ANA: Positive in 60-80% (associated with increased uveitis risk) [1]
• RF: Negative (by definition)
• ESR/CRP: Mild-moderate elevation or normal
• HLA-DRB1: Various alleles associated with early-onset disease

Uveitis Association:

• Occurs in 20-30% of oligoarticular JIA patients [4]
• Highest risk: ANA-positive, female, young age at onset (less than 7 years), disease duration less than 4 years
• Chronic anterior uveitis (insidious onset, asymptomatic early)
• Requires regular screening (see Investigations section)

Prognosis:

• Persistent oligoarticular: Generally good; 40-60% achieve remission [7]
• Extended oligoarticular: More aggressive; resembles polyarticular JIA in behaviour and prognosis

---

2. Polyarticular RF-Negative JIA (20-30% of JIA)

Definition: Arthritis affecting ≥5 joints during the first 6 months of disease; RF negative. [2]

Clinical Features:

Laboratory Features:

• RF: Negative (by definition)
• ANA: Positive in 20-40%
• ESR/CRP: Variable; often moderately elevated
• HLA-DRB1: Associations with certain alleles

Prognosis:

• Variable disease course
• Risk of progressive joint damage if inadequately treated
• Moderate disability in 30-40% without aggressive therapy [7]

---

3. Polyarticular RF-Positive JIA (5-10% of JIA)

Definition: Arthritis affecting ≥5 joints during the first 6 months of disease; RF positive on ≥2 occasions ≥3 months apart. [2]

Clinical Features:

Laboratory Features:

• RF: Positive (by definition; usually high titre IgM RF)
• Anti-CCP: Often positive (associated with erosive disease)
• ANA: May be positive
• ESR/CRP: Typically elevated

Prognosis:

• Most aggressive JIA subtype [1]
• High risk of erosive, destructive arthritis
• Significant functional disability without aggressive treatment
• Clinically and prognostically similar to adult RA
• Requires early DMARD and biologic therapy [5]

---

4. Systemic JIA (5-15% of JIA)

Definition: Arthritis in one or more joints with (or preceded by) documented quotidian fever of ≥2 weeks' duration, plus at least one of: evanescent rash, generalised lymphadenopathy, hepatomegaly/splenomegaly, or serositis. [2]

Clinical Features:

Exam Detail: Systemic Features (defining characteristics):

1. Quotidian Fever

   • Daily high spiking fevers (often 39-40°C or higher)
   • Rapid return to baseline or below normal (afebrile periods)
   • Usually occurs in evening/night
   • Duration: ≥2 weeks required for diagnosis
   • Persists despite broad-spectrum antibiotics

2. Evanescent Rash

   • Salmon-pink, macular or urticarial rash
   • Migratory; appears with fever spikes
   • Distribution: trunk, proximal extremities (spares face in many cases)
   • Koebner phenomenon: Induced by heat, scratching, or trauma
   • Non-pruritic
   • Difficult to photograph (comes and goes rapidly)

3. Lymphadenopathy

   • Generalised, painless lymph node enlargement
   • Must differentiate from malignancy (lymphoma, leukaemia)

4. Hepatosplenomegaly

   • Hepatomegaly more common than splenomegaly
   • Associated with systemic inflammation

5. Serositis

   • Pericarditis: Most common; usually asymptomatic but can cause chest pain, effusion
   • Pleuritis: Less common; may cause pleuritic chest pain
   • Rarely: Peritonitis

Articular Features:

• Arthritis may be absent initially (can develop months after systemic onset)
• When present: Polyarticular pattern most common
• Can affect any joint including hips, cervical spine

Laboratory Features:

Macrophage Activation Syndrome (MAS):

MAS is a life-threatening complication occurring in 10-20% of sJIA patients, representing secondary haemophagocytic lymphohistiocytosis. [9]

Clinical Features of MAS:

• Persistent fever (continuous rather than quotidian)
• Worsening hepatosplenomegaly
• CNS symptoms: Lethargy, confusion, seizures, coma
• Bleeding manifestations: Purpura, mucosal bleeding
• Rapid clinical deterioration

Laboratory Features of MAS (2016 Classification Criteria): [9]

• Ferritin > 684 ng/mL (usually much higher; often > 10,000) PLUS any two of:
  • Platelet count ≤181 × 10⁹/L (dropping platelet count is key sign)
  • AST > 48 U/L
  • Triglycerides > 156 mg/dL (1.76 mmol/L)
  • Fibrinogen ≤360 mg/dL (3.6 g/L)
• Additional features: Pancytopenia, coagulopathy, high lactate dehydrogenase (LDH)
• Bone marrow: Haemophagocytosis (not required for diagnosis; may be absent early)

MAS Triggers:

• Disease flare
• Infections (particularly viral, e.g., EBV, CMV)
• Medication changes (NSAIDs, aspirin, methotrexate initiation)
• Biologics (rare; case reports with IL-6 inhibitors)

Prognosis of sJIA:

• Heterogeneous outcomes
• Some achieve remission with treatment; others have chronic refractory disease
• Long-term sequelae: Destructive arthritis, growth failure, amyloidosis (rare in modern era)
• MAS mortality: 8-10% despite treatment [9]

---

5. Enthesitis-Related Arthritis (10-20% of JIA)

Definition: Arthritis AND enthesitis, OR arthritis OR enthesitis with at least two of: sacroiliac joint tenderness and/or inflammatory lumbosacral pain, HLA-B27 positivity, family history of HLA-B27-associated disease, anterior uveitis, or onset in male > 6 years old. [2]

Clinical Features:

Laboratory Features:

• HLA-B27: Positive in 70-90% [1]
• ANA/RF: Typically negative
• ESR/CRP: Variable elevation

Prognosis:

• Risk of progression to ankylosing spondylitis in adulthood
• Chronic course in many patients
• Uveitis risk lower than oligoarticular JIA but can be severe (acute anterior uveitis)

---

6. Psoriatic Arthritis (5-10% of JIA)

Definition: Arthritis AND psoriasis, OR arthritis with at least two of: dactylitis, nail changes (pitting or onycholysis), psoriasis in first-degree relative. [2]

Clinical Features:

• diffuse swelling of entire finger or toe | | Nail changes | Pitting, onycholysis (separation of nail from nail bed), ridging | | Psoriasis | May precede, coincide with, or follow arthritis (arthritis can occur years before skin disease) | | Temporomandibular joint | Not uncommonly affected |

Laboratory Features:

• ANA: Positive in 40-60%
• RF: Negative
• ESR/CRP: Variable

Prognosis:

• Variable; can range from mild to severe destructive arthritis
• Uveitis risk intermediate

---

7. Undifferentiated Arthritis

Arthritis that does not fulfil criteria for any category OR fulfils criteria for more than one category. [2]

---

General Clinical Examination Findings

Articular Findings

Inspection:

• Joint swelling (may be subtle in deep joints like hips)
• Erythema (usually absent or minimal - septic arthritis should be considered if marked erythema)
• Deformity (flexion contractures, valgus/varus deformities)
• Muscle wasting (atrophy of muscles around affected joints)
• Leg length discrepancy (measure from anterior superior iliac spine to medial malleolus)

Palpation:

• Warmth (subtle; high fever or extreme warmth suggests infection)
• Effusion (ballottement of patella, fluid thrill)
• Synovial thickening (boggy, doughy feel)
• Tenderness (often less than expected given degree of inflammation)

Range of Motion:

• Reduced active and passive ROM
• Pain at end of range
• Flexion contractures (loss of full extension)

Functional Assessment:

• Gait abnormalities (antalgic gait, toe-walking if ankle involvement)
• Inability to perform age-appropriate tasks (e.g., buttoning, writing, running)
• Morning stiffness > 15 minutes (hallmark of inflammatory arthritis)

Extra-Articular Findings by Subtype

Systemic JIA:

• Fever: Document temperature curve over 24-48 hours
• Rash: May need to observe during fever spike; photograph if possible
• Lymphadenopathy: Generalised; document size and distribution
• Hepatosplenomegaly: Measure liver and spleen span
• Serositis: Pericardial friction rub (rare), pleural rub

Enthesitis-Related Arthritis:

• Enthesitis: Tenderness at Achilles insertion, plantar fascia insertion, tibial tuberosity
• Schober's test: Reduced lumbar spine flexion (if sacroiliitis present)

Psoriatic Arthritis:

• Skin: Psoriatic plaques (scalp, extensor surfaces, gluteal cleft, umbilicus)
• Nails: Pitting (small depressions), onycholysis, oil spots
• Dactylitis: Entire digit swollen

---

5. Differential Diagnosis

The differential diagnosis of JIA is broad and includes infectious, malignant, inflammatory, and mechanical causes of arthritis in children.

Key Differentials

Red Flags Suggesting Alternative Diagnosis

• Acute monoarthritis with high fever and severe pain: Septic arthritis until proven otherwise
• Bone pain (worse at night, relieved by NSAIDs): Malignancy (leukaemia, neuroblastoma, bone tumours)
• Pancytopenia, unexplained bruising/bleeding: Leukaemia or bone marrow failure
• Severe systemic features disproportionate to arthritis: Malignancy, vasculitis
• Neurological signs: SLE, vasculitis, infection, malignancy
• Severe abdominal pain: HSP, IBD, polyarteritis nodosa
• Lack of morning stiffness: Mechanical/non-inflammatory causes
• Pain worse with activity, better with rest: Mechanical causes (opposite of inflammatory arthritis)

---

6. Investigations

Diagnostic Approach

There is no single diagnostic test for JIA. Diagnosis is clinical, based on history and examination findings, with investigations used to:

1. Support the diagnosis (inflammatory markers, imaging)
2. Classify the JIA subtype (ANA, RF, HLA-B27)
3. Exclude differential diagnoses (infection, malignancy)
4. Assess disease activity and organ involvement
5. Screen for complications (uveitis)
6. Monitor treatment response and adverse effects

First-Line Investigations

Blood Tests

Additional Tests in Systemic JIA

If systemic JIA suspected or confirmed, additional tests to assess for MAS risk:

Excluding Differential Diagnoses

Imaging

Plain Radiography (X-ray)

Indications:

• Baseline imaging of affected joints (particularly in polyarticular disease)
• Exclude fracture, malignancy, other bone pathology
• Assess for erosions/joint damage in established disease

Findings:

• Early disease: Often normal, or soft tissue swelling, periarticular osteopaenia
• Established disease: Joint space narrowing, erosions, subchondral cysts, ankylosis
• Growth disturbances: Accelerated epiphyseal maturation (enlarged epiphysis), leg length discrepancy

Limitations:

• Poor sensitivity for early synovitis
• Radiation exposure (minimise in children)

Ultrasound (USS)

Indications:

• Detect synovitis (more sensitive than clinical examination)
• Guide intra-articular corticosteroid injections
• Assess for effusion, synovial hypertrophy, power Doppler signal (active inflammation)

Advantages:

• No radiation
• Real-time assessment
• Can assess multiple joints
• Detects subclinical synovitis

Findings:

• Synovial hypertrophy (thickened, hypoechoic synovium)
• Joint effusion
• Power Doppler signal (increased vascularity = active inflammation)
• Erosions (better detected on MRI/X-ray)

Magnetic Resonance Imaging (MRI)

Indications:

• Temporomandibular joint (TMJ): MRI is gold standard for detecting TMJ arthritis (often subclinical) [10]
• Sacroiliac joints: Detect sacroiliitis in ERA (X-ray changes occur late)
• Hip arthritis: Assess for synovitis, cartilage damage, avascular necrosis
• Cervical spine: If neck pain/stiffness (atlantoaxial instability risk in polyarticular JIA)
• Unclear diagnosis: Differentiate JIA from malignancy, osteomyelitis, CRMO

Findings:

• Synovitis (synovial enhancement with gadolinium)
• Bone marrow oedema (high signal on STIR/T2 fat-sat sequences)
• Erosions (sensitive detection)
• Cartilage loss

Advantages:

• Most sensitive for early inflammation
• No radiation
• Excellent soft tissue contrast

Disadvantages:

• Expensive
• May require sedation/general anaesthesia in young children
• Long scan times

Joint Aspiration

Indications:

• Acute monoarthritis: Mandatory to exclude septic arthritis
• Unclear diagnosis: Differentiate inflammatory vs non-inflammatory arthritis

NOT routinely performed in established JIA

Synovial Fluid Analysis:

Ophthalmological Screening for Uveitis

Chronic anterior uveitis is a major cause of morbidity in JIA, potentially causing permanent vision loss. Regular screening with slit-lamp examination by an ophthalmologist is mandatory. [4]

Uveitis Screening Frequency (ACR/AAP 2019 Recommendations)

Risk stratification based on:

1. JIA subtype: Oligoarticular and polyarticular RF-negative have highest risk
2. ANA status: ANA-positive increases risk
3. Age at onset: Younger age (less than 7 years) increases risk
4. Disease duration: Highest risk in first 4-7 years after arthritis onset

Note: ERA-associated uveitis is acute anterior uveitis (symptomatic: red eye, pain, photophobia), in contrast to the chronic anterior uveitis of oligoarticular JIA (asymptomatic). [4]

Ophthalmological Findings in JIA-Associated Uveitis

• Early: Cells and flare in anterior chamber (detected on slit-lamp examination)
• Complications:
  • Posterior synechiae (iris adhesions to lens)
  • Band keratopathy (calcium deposition in cornea)
  • Cataract
  • Glaucoma
  • Macular oedema
  • Phthisis bulbi (end-stage shrunken, non-functional eye)

Treatment Monitoring

Pre-Treatment Screening

Before starting DMARDs or biologics:

Tuberculosis Screening Before Biologics

Before starting TNF inhibitors (etanercept, adalimumab), mandatory TB screening:

• Tuberculin skin test (TST, Mantoux) OR Interferon-gamma release assay (IGRA) (QuantiFERON-TB Gold, T-SPOT.TB)
• Chest X-ray
• If positive: Treat latent TB before starting biologic (usually isoniazid for 6 months)

Ongoing Monitoring on Treatment

---

7. Management

The management of JIA is multidisciplinary, with the overarching goal of achieving inactive disease (no active arthritis, no systemic features, normal inflammatory markers, no uveitis progression) to prevent long-term joint damage, preserve function, and optimise quality of life. [5,7]

Modern treatment strategies emphasise early aggressive therapy with disease-modifying drugs and biologics to achieve remission, rather than a prolonged "step-up" approach. [5,7]

Management Goals

1. Inactive Disease: No clinical or laboratory evidence of active disease [5,7]
2. Prevent Joint Damage: Avoid erosions, contractures, growth disturbances
3. Prevent/Manage Uveitis: Regular screening; treat aggressively to prevent vision loss
4. Optimise Function: Normal or near-normal physical function, participation in activities
5. Minimise Treatment Toxicity: Balance efficacy with safety
6. Support Psychosocial Well-being: Address impact on child and family

Multidisciplinary Team

Non-Pharmacological Management

Physiotherapy

Essential component of JIA management:

• Maintain and improve joint range of motion
• Strengthen muscles around affected joints
• Improve overall fitness and endurance
• Provide pain relief (heat, hydrotherapy)
• Prevent contractures

Exercise Prescription:

• Low-impact activities: Swimming, cycling (excellent for maintaining fitness without joint stress)
• Range of motion exercises: Daily stretching
• Strengthening: Age-appropriate resistance exercises
• Balance: Avoid prolonged immobility (worsens stiffness)

Occupational Therapy

• Splinting: Night splints to prevent/treat contractures (e.g., wrist splints, knee extension splints)
• Adaptive devices: Aids for daily activities (e.g., modified pencil grips, dressing aids)
• Joint protection: Techniques to minimise joint stress during activities
• School liaison: Ensure appropriate accommodations (extra time, physical education modifications)

Psychosocial Support

• Address impact of chronic disease on child and family
• Pain management strategies (cognitive-behavioural therapy, relaxation techniques)
• Adherence support (particularly for methotrexate, which can cause nausea and aversion)
• School reintegration after diagnosis

Pharmacological Management

The pharmacological approach is tailored to JIA subtype, disease severity, and prognostic factors. Current ACR/AF guidelines (2019-2021) provide evidence-based recommendations. [5,8]

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Role: Symptomatic relief; NOT disease-modifying (do not prevent joint damage)

Commonly Used NSAIDs in JIA:

• Naproxen: 10-20 mg/kg/day divided twice daily (maximum 1000 mg/day)
• Ibuprofen: 30-40 mg/kg/day divided 3-4 times daily (maximum 2400 mg/day)

Efficacy:

• Provide pain relief and reduce inflammation
• Insufficient as monotherapy in most patients (except mildest oligoarticular JIA)

Adverse Effects:

• Gastrointestinal: Abdominal pain, nausea, peptic ulcer (rare in children)
• Renal: Renal impairment (rare; monitor renal function)
• Hepatic: Transaminitis (rare)
• Hypersensitivity reactions

Monitoring: Baseline FBC, renal function, LFTs; repeat if symptoms

---

Intra-Articular Corticosteroid Injections

Role: Rapid control of inflammation in oligoarticular disease; adjunct in polyarticular disease

Indications:

• Oligoarticular JIA: First-line treatment (often combined with NSAIDs) [5]
• Polyarticular JIA: Adjunct to systemic DMARDs for particularly active joints
• Systemic JIA: Less effective (systemic disease requires systemic therapy)

Technique:

• Triamcinolone hexacetonide: Preferred agent (longer duration of action than other corticosteroids)
• Dose: 1 mg/kg per joint (maximum 40 mg for large joints, 20 mg for medium joints)
• Ultrasound guidance: Recommended for accuracy and safety
• Sedation/General anaesthesia: Often required in young children

Efficacy:

• 40-70% of patients achieve disease control for ≥6-12 months after injection [5]
• May avoid or delay need for systemic therapy in oligoarticular JIA

Adverse Effects:

• Local: Subcutaneous atrophy, depigmentation (risk reduced with triamcinolone hexacetonide)
• Systemic: Transient suppression of hypothalamic-pituitary-adrenal (HPA) axis (rare, clinically insignificant)
• Post-injection flare (rare)

---

Conventional Synthetic DMARDs

Methotrexate

Role: First-line DMARD for JIA (except systemic JIA, where IL-1/IL-6 inhibitors are preferred) [5,11]

Indications:

• Oligoarticular JIA inadequately controlled with NSAIDs and intra-articular steroids
• All polyarticular JIA (RF-negative and RF-positive)
• Psoriatic arthritis
• JIA-associated uveitis (steroid-sparing agent)

Dosing:

• 15 mg/m² per week (range 10-25 mg/m²/week) [11]
• Subcutaneous route preferred over oral (better bioavailability, less GI side effects) [11]
• Folic acid supplementation: 1 mg daily OR 5 mg once weekly (not on same day as methotrexate) to reduce side effects

Efficacy:

• Effective in 60-70% of patients with polyarticular JIA [11]
• Onset of action: 6-12 weeks

Adverse Effects:

• Gastrointestinal: Nausea, vomiting, abdominal pain, anorexia (common; may improve with subcutaneous route and folic acid) [11,13]
• Methotrexate intolerance: Anticipatory nausea, aversion to medication (behavioural/psychological component) [13]
• Hepatotoxicity: Transaminitis (common; usually mild and transient; monitor LFTs)
• Bone marrow suppression: Leucopenia, thrombocytopenia (rare at paediatric doses; monitor FBC)
• Infection risk: Modest increase
• Pulmonary: Methotrexate pneumonitis (rare; presents with cough, dyspnoea; requires immediate discontinuation)
• Teratogenicity: Contraindicated in pregnancy; counsel adolescent females

Monitoring: [11]

• FBC, LFTs: Every 2-4 weeks for first 3 months, then every 3 months once stable
• Renal function: Baseline and periodically
• Pregnancy test in adolescent females (before starting and as needed)

Management of Methotrexate Intolerance: [13]

• Switch from oral to subcutaneous route
• Optimise folic acid supplementation
• Anti-emetics before dose (ondansetron)
• Behavioural strategies (distraction, relaxation)
• If severe and refractory: Switch to alternative DMARD or biologic

Sulfasalazine

Role: Alternative DMARD; used primarily in enthesitis-related arthritis (ERA)

Dosing: 30-50 mg/kg/day divided twice daily (maximum 2-3 g/day)

Efficacy: Modestly effective in ERA; less effective than methotrexate in polyarticular JIA

Adverse Effects: GI upset, rash, cytopenias (rare)

Leflunomide

Role: Alternative DMARD if methotrexate not tolerated or ineffective; less commonly used in children

Dosing: Weight-based loading dose, then maintenance

Adverse Effects: Similar to methotrexate; teratogenic

---

Biologic DMARDs

Biologic agents have revolutionised JIA management, particularly for patients with inadequate response to conventional DMARDs. [5,6,14]

TNF Inhibitors

Mechanism: Inhibit tumour necrosis factor-alpha (TNF-α), a central pro-inflammatory cytokine

Licensed TNF Inhibitors in JIA:

1. Etanercept (TNF receptor fusion protein)

   • Dosing: 0.8 mg/kg subcutaneous once weekly (maximum 50 mg)
   • Indications: Polyarticular JIA (RF- and RF+), extended oligoarticular JIA, ERA, psoriatic arthritis
   • Efficacy: 70-80% ACR Pedi 30 response in clinical trials [17,19]

2. Adalimumab (Fully human monoclonal anti-TNF antibody)

   • Dosing: Weight-based (15-30 kg: 20 mg every 2 weeks; > 30 kg: 40 mg every 2 weeks) subcutaneous
   • Indications: Polyarticular JIA, ERA, psoriatic arthritis; also effective for JIA-associated uveitis (refractory to methotrexate) [12]
   • Efficacy: Similar to etanercept for arthritis [17,19]; superior to etanercept for uveitis [12]

3. Infliximab (Chimeric monoclonal anti-TNF antibody)

   • Dosing: 3-6 mg/kg IV at 0, 2, 6 weeks, then every 8 weeks
   • Indications: Less commonly used in JIA; may be used off-label
   • Note: Higher immunogenicity than fully human antibodies

Efficacy:

• 60-80% of patients achieve ACR Pedi 30 response (30% improvement in arthritis measures) [17,19]
• 30-50% achieve ACR Pedi 70 [17,19]
• Significant improvement in quality of life, function [17]

Comparative Efficacy: Etanercept and adalimumab have broadly similar efficacy for arthritis, but adalimumab appears superior for JIA-associated uveitis. [12,17,19]

Adverse Effects:

• Infections: Increased risk of bacterial infections (particularly respiratory, skin/soft tissue)
• Tuberculosis reactivation: Mandatory TB screening before initiation
• Injection site reactions: Common, usually mild
• Immunogenicity: Anti-drug antibodies (more common with infliximab and adalimumab than etanercept); may reduce efficacy
• Malignancy: Unclear; possible small increased risk of lymphoma (data limited in paediatric population)
• Demyelination: Rare; case reports of CNS demyelination
• Lupus-like syndrome: Rare

Monitoring:

• FBC, LFTs every 3-6 months
• Annual TB screening (CXR)
• Monitor for infections
• Ensure vaccinations up to date (avoid live vaccines during treatment)

IL-6 Inhibitors

Mechanism: Block interleukin-6 receptor, reducing IL-6-mediated inflammation

Tocilizumab (Humanised monoclonal anti-IL-6 receptor antibody)

Dosing:

• IV: 8-12 mg/kg every 2 weeks (weight-based)
• Subcutaneous: Weight-based dosing available

Indications:

• Systemic JIA: First-line biologic (preferred over TNF inhibitors) [8,14]
• Polyarticular JIA (if TNF inhibitor inadequate/not tolerated)

Efficacy in Systemic JIA:

• Highly effective: 85-90% achieve inactive disease in clinical trials [14]
• Rapidly controls systemic features (fever, rash) and arthritis
• Reduces risk of MAS [14]

Adverse Effects:

• Infections: Increased risk (similar to TNF inhibitors)
• Neutropenia: Common; usually asymptomatic; monitor FBC
• Transaminitis: Common; monitor LFTs
• Hyperlipidaemia: Elevated cholesterol and triglycerides (monitor lipid profile)
• GI perforation: Rare; case reports (higher risk if history of diverticulitis)
• Masking of fever: IL-6 inhibition prevents fever response; infections may present without fever

Monitoring:

• FBC, LFTs: Every 3-6 months
• Lipid profile: Baseline and periodically
• TB screening before initiation

IL-1 Inhibitors

Mechanism: Block interleukin-1, a key cytokine in autoinflammatory conditions

IL-1 Inhibitors in Systemic JIA:

1. Anakinra (IL-1 receptor antagonist)

   • Dosing: 1-2 mg/kg/day subcutaneous daily (maximum 100 mg)
   • Efficacy: Effective in systemic JIA, particularly systemic features [8]
   • Adverse Effects: Injection site reactions (very common, painful); infections

2. Canakinumab (Monoclonal anti-IL-1β antibody)

   • Dosing: 4 mg/kg subcutaneous every 4 weeks (maximum 300 mg)
   • Efficacy: Highly effective in systemic JIA; 60-85% response rates [8]
   • Advantages: Less frequent dosing (every 4 weeks) vs anakinra (daily); fewer injection site reactions
   • Adverse Effects: Infections; rare MAS (paradoxical; case reports)

Indications: Systemic JIA (first-line biologic options alongside tocilizumab) [8]

Comparative Efficacy: IL-1 and IL-6 inhibitors both highly effective for systemic JIA; choice depends on patient factors, availability, clinician preference. [8]

Other Biologics

Abatacept (CTLA4-Ig; T-cell co-stimulation blocker)

• Indications: Polyarticular JIA (particularly if TNF inhibitor inadequate/not tolerated) [19]
• Dosing: IV weight-based or subcutaneous weekly
• Efficacy: 60-70% ACR Pedi 30 response [19]

---

Corticosteroids (Systemic)

Role: Bridge therapy; short-term use to control severe disease while awaiting DMARD/biologic effect

Indications:

• Severe polyarticular or systemic JIA requiring rapid disease control
• Macrophage Activation Syndrome (high-dose pulse methylprednisolone)
• JIA-associated uveitis (oral or topical)

Dosing:

• Low-dose oral: Prednisolone 0.2-0.5 mg/kg/day
• Pulse IV: Methylprednisolone 10-30 mg/kg (maximum 1 g) for 3 days (severe flares, MAS)

Adverse Effects:

• Growth suppression: Significant concern in children; minimise dose and duration
• Weight gain, Cushingoid features
• Hypertension
• Hyperglycaemia
• Osteoporosis (with prolonged use)
• Avascular necrosis (rare)
• Infection risk
• Adrenal suppression: Risk with prolonged use; taper slowly

Goal: Avoid long-term systemic corticosteroids wherever possible; use DMARDs/biologics as steroid-sparing agents

---

Subtype-Specific Treatment Algorithms

Oligoarticular JIA

Exam Detail: Step 1: Mild Disease (1-2 joints, minimal functional impact)

• NSAIDs
• Intra-articular corticosteroid injections [5]
• Physiotherapy

Step 2: Inadequate Response or Extended Oligoarticular (≥5 joints after 6 months)

• Add Methotrexate 15 mg/m²/week [5,11]

Step 3: Methotrexate Inadequate Response (≥3-6 months trial)

• Add TNF inhibitor (etanercept or adalimumab) [5]

Step 4: Refractory Disease

• Switch to alternative biologic (tocilizumab, abatacept) [5]

Uveitis Management (if present):

• Topical corticosteroids (first-line for uveitis)
• Methotrexate (steroid-sparing)
• Adalimumab (if refractory to methotrexate) [12]
• Ophthalmology co-management essential

---

Polyarticular JIA (RF-Negative and RF-Positive)

Exam Detail: Step 1: Initial Therapy

• NSAIDs
• Methotrexate 15 mg/m²/week (start early) [5,11]
• Intra-articular corticosteroids for particularly active joints
• Consider short course oral prednisolone (bridge therapy if severe)

Step 2: Methotrexate Inadequate Response (≥3-6 months trial)

• Add TNF inhibitor (etanercept, adalimumab) OR switch to methotrexate + TNF inhibitor [5,14]

Step 3: TNF Inhibitor Inadequate Response

• Switch to alternative TNF inhibitor OR
• Switch to tocilizumab, abatacept, or other biologic [5,14]

RF-Positive Polyarticular JIA:

• Treat aggressively (similar to adult RA) due to high risk of erosive disease [5]
• Early combination therapy (methotrexate + biologic) may be considered [5]

---

Systemic JIA

Exam Detail: Step 1: Initial Systemic Features

• NSAIDs (provide some symptom relief but insufficient alone)
• First-line biologic: IL-1 inhibitor (anakinra or canakinumab) OR IL-6 inhibitor (tocilizumab) [8]
• NOT methotrexate monotherapy (ineffective for systemic features) [8]
• NOT TNF inhibitors first-line (less effective than IL-1/IL-6 inhibitors for systemic features) [8]

Step 2: Persistent Systemic Features Despite IL-1/IL-6 Inhibitor

• Switch to alternative IL-1 or IL-6 inhibitor [8]
• Consider combination therapy

Step 3: Refractory Systemic Disease

• Trial of alternative biologics
• Haematopoietic stem cell transplantation (very rare, extreme cases)

Arthritis Component (if systemic features controlled but arthritis persists):

• Add methotrexate [8]
• Consider TNF inhibitor if IL-1/IL-6 inhibitor inadequate for arthritis

Macrophage Activation Syndrome (MAS):

• Medical emergency: ICU care
• High-dose IV methylprednisolone: 10-30 mg/kg/day for 3-5 days [9]
• Ciclosporin: 2-5 mg/kg/day (used in many centres; reduces T-cell activation) [9]
• Anakinra: IL-1 inhibition may be effective (some evidence) [9]
• Etoposide: Reserved for refractory MAS (chemotherapy agent used in HLH protocols)
• Supportive care: Transfusions, coagulopathy management
• Stop potential triggers (NSAIDs, methotrexate if just started)

---

Enthesitis-Related Arthritis (ERA)

Exam Detail: Step 1: Initial Therapy

• NSAIDs
• Intra-articular corticosteroids (for peripheral arthritis)
• Sulfasalazine OR Methotrexate [5]
• Physiotherapy (emphasise spinal mobility exercises)

Step 2: Inadequate Response

• Add TNF inhibitor (etanercept, adalimumab, or infliximab) [5]
• TNF inhibitors highly effective for ERA, including axial involvement

Step 3: TNF Inhibitor Inadequate Response

• Switch to alternative TNF inhibitor OR
• IL-17 inhibitor (secukinumab - emerging evidence; used in adult ankylosing spondylitis)

Uveitis (if acute anterior uveitis develops):

• Topical corticosteroids
• Refer to ophthalmology urgently

---

Special Considerations

Temporomandibular Joint (TMJ) Involvement

• Occurs in 30-40% of JIA patients (often subclinical) [10]
• MRI is gold standard for diagnosis (clinical examination insensitive) [10]
• Treatment: Methotrexate, intra-articular TMJ corticosteroid (under image guidance), biologics
• Orthodontic referral if malocclusion, micrognathia

Growth Monitoring and Management

• Plot growth (height, weight) at every visit
• Leg length discrepancy: Measure; consider shoe lift if significant (> 2 cm)
• Growth hormone: May be considered in severe growth failure (limited evidence)
• Optimise disease control: Best way to promote normal growth is to control inflammation and minimise corticosteroid use

Transition to Adult Care

• JIA may persist into adulthood in 30-50% of patients [7]
• Structured transition planning from age 12-14 years
• Transfer to adult rheumatology services at age 16-18 years (varies by region)
• Ensure continuity of uveitis screening in adult care

Vaccination

• Live vaccines (MMR, varicella, BCG): Contraindicated during biologics, methotrexate (high dose), systemic corticosteroids
• Ideally, complete routine childhood vaccinations before starting immunosuppression
• Inactivated vaccines (influenza, pneumococcal, HPV): Safe and recommended; may have reduced immunogenicity
• Annual influenza vaccine: Recommended for all JIA patients on immunosuppression

---

8. Complications

Joint Complications

Joint Damage and Erosions

• Polyarticular RF-positive JIA: Highest risk of erosive, destructive arthritis [1]
• Radiographic erosions: Subchondral bone loss, joint space narrowing, ankylosis
• Functional impairment: Reduced range of motion, contractures, deformities
• Prevention: Early aggressive treatment with DMARDs/biologics

Contractures

• Fixed flexion deformities from chronic synovitis and muscle imbalance
• Common sites: Knees (flexion contracture), wrists (flexion), ankles (equinus)
• Prevention: Physiotherapy, splinting, disease control

Growth Disturbances

Local Growth Abnormalities:

• Leg length discrepancy: Accelerated growth from knee hyperaemia (chronic inflammation) → longer affected leg; OR growth plate damage → shorter affected leg
• Micrognathia: TMJ arthritis → impaired mandibular growth → small, retruded jaw [10]
• Brachydactyly: Short digits from phalangeal growth plate damage

Generalised Growth Impairment:

• Chronic systemic inflammation (IL-6, IL-1, TNF-α) → suppression of growth hormone axis
• Corticosteroid therapy → direct growth suppression
• Malnutrition → inadequate substrate for growth
• Result: Short stature, delayed puberty

Ocular Complications (JIA-Associated Uveitis)

Chronic anterior uveitis occurs in 20-30% of oligoarticular JIA (highest in ANA-positive young females). [4]

Complications of Untreated/Undertreated Uveitis

Prevention: Regular ophthalmological screening (see Investigations section) and prompt treatment

Treatment of JIA-Associated Uveitis:

• Topical corticosteroids (prednisolone acetate 1%)
• Mydriatics (prevent/break posterior synechiae)
• Methotrexate (steroid-sparing systemic agent) [11]
• Adalimumab (most effective biologic for refractory uveitis) [12]

Macrophage Activation Syndrome (Systemic JIA)

• Occurs in 10-20% of systemic JIA patients [9]
• Mortality: 8-10% despite treatment [9]
• Clinical features: Persistent fever, hepatosplenomegaly, CNS symptoms, bleeding
• Laboratory: Falling platelets, rising ferritin (often > 10,000 μg/L), falling fibrinogen, transaminitis [9]
• Treatment: High-dose corticosteroids, ciclosporin, supportive care [9]

Infection Risk

• Increased infection risk from:
  • Immunosuppressive therapy (methotrexate, biologics, corticosteroids)
  • Impaired immune function from chronic disease
• Common infections: Respiratory, skin/soft tissue, urinary tract
• Serious infections: Pneumonia, sepsis, opportunistic infections (rare)
• Tuberculosis reactivation: Risk with TNF inhibitors (mandatory screening before initiation)
• Varicella: Can be severe in immunosuppressed patients; ensure vaccination if seronegative

Medication Adverse Effects

See Pharmacological Management section for detailed adverse effects of each medication.

Key Concerns:

• Methotrexate: Nausea, hepatotoxicity, bone marrow suppression, teratogenicity [11,13]
• Biologics: Infections, injection site reactions, immunogenicity [17]
• Corticosteroids: Growth suppression, weight gain, osteoporosis, adrenal suppression

Psychosocial Impact

• Chronic pain and disability affect quality of life, school attendance, peer relationships
• Body image concerns (medication side effects, disease manifestations)
• Mental health: Increased risk of anxiety, depression
• Family stress
• Management: Psychosocial support, counselling, peer support groups

---

9. Prognosis and Outcomes

Modern Era Outcomes

The prognosis of JIA has improved dramatically over the past two decades with the introduction of biologic DMARDs and early aggressive treatment strategies. [5,7]

Remission Rates

Prognostic Factors

Good Prognosis

• Oligoarticular JIA (persistent, not extended)
• Early age at onset (less than 6 years) for oligoarticular
• Absence of RF, anti-CCP
• Early treatment and achievement of inactive disease
• Good adherence to therapy and follow-up

Poor Prognosis

• Polyarticular RF-positive JIA: Most severe subtype; high risk of erosive disease [1]
• Extended oligoarticular JIA: Worse outcomes than persistent oligoarticular
• Systemic JIA: Variable; MAS risk, chronic arthritis risk
• Presence of RF, anti-CCP (markers of erosive disease)
• Hip involvement (higher disability risk)
• Delayed diagnosis and treatment
• Non-adherence to therapy

Outcomes by Subtype

Oligoarticular JIA

• Persistent oligoarticular: 40-60% achieve remission; generally good prognosis [7]
• Extended oligoarticular: Behaves more like polyarticular JIA; 20-30% remission [7]
• Uveitis: Main cause of long-term morbidity; risk of vision loss if undetected/untreated [4]

Polyarticular JIA

• RF-negative: Variable outcomes; 30-50% achieve remission [7]
• RF-positive: Poorest prognosis; chronic erosive arthritis in majority; resembles adult RA [1]

Systemic JIA

• Monocyclic (single episode, then remission): 30-40% of sJIA [8]
• Polycyclic (recurrent flares): 30-40% of sJIA [8]
• Chronic arthritis: 20-30% develop persistent polyarticular arthritis [8]
• MAS: Life-threatening complication; 8-10% mortality [9]

Enthesitis-Related Arthritis

• Many progress to ankylosing spondylitis in adulthood
• Chronic axial and peripheral arthritis common
• May require long-term biologic therapy

Long-Term Outcomes

Transition to Adulthood

• 30-50% of JIA patients have ongoing active disease in adulthood [7]
• Persistence varies by subtype:
  • "Oligoarticular: 20-30% active in adulthood"
  • "Polyarticular RF+: 60-80% active in adulthood"
  • "Systemic JIA: 30-50% active in adulthood"
• Transition to adult rheumatology care required

Functional Disability

• Modern era: 10-20% have significant functional disability [7]
• Pre-biologic era: 30-50% had significant disability (historical data)
• Improvement reflects impact of early aggressive therapy

Employment and Education

• Majority achieve normal education and employment outcomes with optimal disease control
• Persistent disease or late diagnosis associated with lower educational attainment, employment rates

Mortality

• Overall mortality: Low in modern era (less than 1%)
• Systemic JIA with MAS: 8-10% mortality [9]
• Amyloidosis: Rare complication in modern era (due to improved disease control); can cause renal failure

---

10. Prevention

Primary Prevention

There are no proven strategies to prevent the onset of JIA. The condition arises from complex gene-environment interactions, and specific environmental triggers have not been definitively identified.

Secondary Prevention (Early Detection and Treatment)

Early Diagnosis

• Maintain high index of suspicion in children with:
  • Persistent joint swelling (≥6 weeks)
  • Morning stiffness
  • Limp or refusal to walk (young children)
  • Systemic symptoms (fever, rash) with arthritis
• Prompt referral to paediatric rheumatology

Uveitis Screening

• Adherence to recommended screening schedules prevents vision loss [4]
• High-risk patients: Slit-lamp examination every 3 months [4]
• Educate families on importance of ophthalmology appointments (even when asymptomatic)

Tertiary Prevention (Prevent Complications)

Prevent Joint Damage

• Early aggressive therapy with DMARDs/biologics to achieve inactive disease [5,7]
• Regular monitoring and treatment escalation if inadequate response

Prevent Growth Impairment

• Optimise disease control (reduces systemic inflammation)
• Minimise corticosteroid use (use steroid-sparing DMARDs/biologics)
• Monitor growth (height, weight) at every visit

Prevent Infection

• Ensure vaccinations up to date before starting immunosuppression
• Annual influenza vaccine
• TB screening before TNF inhibitors
• Educate families on infection risk and when to seek medical attention

Prevent Treatment Toxicity

• Regular monitoring of FBC, LFTs, renal function on methotrexate and biologics [11]
• Dose adjustments or medication changes if toxicity develops

---

11. Evidence and Guidelines

Key Guidelines

ACR/Arthritis Foundation JIA Treatment Guidelines (2019-2021)

The American College of Rheumatology and Arthritis Foundation published updated evidence-based guidelines for JIA management:

1. 2019 Guideline for the Treatment of Juvenile Idiopathic Arthritis: General recommendations [PMID: 31021516]

2. 2021 Guideline for Oligoarthritis, TMJ Arthritis, and Systemic JIA: [5,8]

   • Oligoarthritis: NSAIDs and intra-articular steroids first-line; methotrexate if inadequate; TNF inhibitors if methotrexate fails [5]
   • Systemic JIA: IL-1 or IL-6 inhibitors first-line (NOT methotrexate alone or TNF inhibitors first-line) [8]
   • TMJ arthritis: MRI for diagnosis; methotrexate + intra-articular steroids; biologics if refractory [5]

EULAR/PReS Recommendations

3. EULAR/PReS Recommendations for the Diagnosis and Management of Still's Disease (2024): [PMID: 39317417]
   • Covers both systemic JIA and adult-onset Still's disease
   • Emphasises IL-1/IL-6 inhibitors for systemic features [7]

BSPAR UK Guidelines

4. British Society for Paediatric and Adolescent Rheumatology (BSPAR): UK-specific guidelines for JIA management

Uveitis Screening Guidelines

5. ACR/AAP Guidelines for Screening, Monitoring, and Treatment of JIA-Associated Uveitis (2019): [PMID: not provided; reference 4]
   • Risk-based screening frequency [4]
   • High-risk (ANA+, young, oligoarticular): Every 3 months [4]

Key Evidence

Classification

6. Petty RE, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis. J Rheumatol. 2004;31(2):390-392. [PMID: 14760812] [2]

   • Established the ILAR classification system (7 categories)

7. Martini A, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis. J Rheumatol. 2019;46(2):190-197. [PMID: 30275259] [2]

   • PRINTO initiative to revise classification criteria

Epidemiology and Outcomes

8. Martini A, et al. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022;8(1):5. [PMID: 35087087] [1]
   • Comprehensive review of JIA epidemiology, pathophysiology, management

Macrophage Activation Syndrome

9. Ravelli A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2016;68(3):566-576. [PMID: 26314788] [9]
   • Established classification criteria for MAS in sJIA
   • Ferritin > 684 ng/mL plus 2 of: platelet ≤181, AST > 48, triglycerides > 156, fibrinogen ≤360

Methotrexate

10. Ferrara G, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46. [PMID: 29996864] [11]

    • Dosing: 15 mg/m²/week; subcutaneous route preferred
    • Folic acid supplementation reduces side effects
    • Monitoring: FBC, LFTs every 2-4 weeks initially, then every 3 months

11. Wibrand C, et al. Methotrexate Intolerance in Juvenile Idiopathic Arthritis: Definition, Risks, and Management. Paediatr Drugs. 2024;26(5):537-549. [PMID: 39044097] [13]

    • Methotrexate intolerance common (nausea, aversion)
    • Management: Switch to subcutaneous, anti-emetics, behavioural strategies

Biologics

12. Chang MH, et al. Uveitis in Children and Adolescents. Rheum Dis Clin North Am. 2021;47(4):619-635. [PMID: 34635295] [12]

    • Adalimumab effective for JIA-associated uveitis refractory to methotrexate

13. Shenoi S, et al. Treatment of non-systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2024;20(3):145-157. [PMID: 38321298] [14]

    • Review of treatment strategies for non-systemic JIA
    • TNF inhibitors highly effective; 60-80% response rates

14. Hinze CH, et al. Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2023;19(12):776-788. [PMID: 37923864] [8]

    • IL-1 and IL-6 inhibitors first-line for systemic JIA
    • Superior to TNF inhibitors for systemic features

15. Ge L, et al. Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis. BMC Pediatr. 2025;25(1):212. [PMID: 40148850] [17]

    • Etanercept and adalimumab have similar efficacy for arthritis

16. Goettel AM, et al. Efficacy and Safety of Abatacept, Adalimumab, and Etanercept in Pediatric Patients With Juvenile Idiopathic Arthritis. J Pediatr Pharmacol Ther. 2021;26(2):157-168. [PMID: 33603579] [19]

    • Review of biologic efficacy and safety in JIA

TMJ Involvement

17. [Implied reference] Temporomandibular joint involvement occurs in 30-40% of JIA patients; MRI is gold standard for diagnosis. [10]

---

12. Examination Focus (MRCPCH / Paediatric Rheumatology)

High-Yield Viva Topics

Exam Detail: #### Viva Question 1: ILAR Classification

Q: "What are the ILAR categories of juvenile idiopathic arthritis? How would you classify a 3-year-old girl with arthritis affecting both knees and one ankle, who is ANA-positive?"

Model Answer:

The ILAR classification divides JIA into seven categories:

1. Oligoarticular (1-4 joints in first 6 months): Subdivided into persistent (≤4 joints throughout) and extended (> 4 joints after 6 months)
2. Polyarticular RF-negative (≥5 joints, RF negative)
3. Polyarticular RF-positive (≥5 joints, RF positive on ≥2 occasions)
4. Systemic (arthritis + quotidian fever ≥2 weeks + rash/lymphadenopathy/hepatosplenomegaly/serositis)
5. Enthesitis-related arthritis (arthritis + enthesitis, or arthritis/enthesitis + ≥2 of: sacroiliac tenderness, HLA-B27+, family history, uveitis, male > 6 years)
6. Psoriatic arthritis (arthritis + psoriasis, or arthritis + ≥2 of: dactylitis, nail changes, psoriasis in first-degree relative)
7. Undifferentiated (does not fit any category or fits > 1 category)

For the described patient:

• 3 joints (both knees, one ankle) = oligoarticular JIA
• ANA-positive = high risk of uveitis (requires regular slit-lamp screening every 3 months)
• If remains ≤4 joints: Persistent oligoarticular JIA
• If progresses to ≥5 joints: Extended oligoarticular JIA (worse prognosis)

---

Viva Question 2: Uveitis Screening

Q: "Why is uveitis screening important in JIA? Which patients are at highest risk, and what is the recommended screening frequency?"

Model Answer:

Importance:

• Chronic anterior uveitis occurs in 20-30% of JIA patients (particularly oligoarticular, ANA-positive)
• Asymptomatic in early stages (silent eye disease)
• Can cause irreversible vision loss if untreated: posterior synechiae, band keratopathy, cataract, glaucoma, blindness
• Regular screening essential to detect and treat before complications develop

Highest Risk:

• Oligoarticular JIA
• ANA-positive
• Female
• Young age at onset (less than 7 years)
• Early disease duration (first 4-7 years)

Screening Frequency (ACR/AAP 2019):

• High risk (oligoarticular/polyarticular RF-, ANA+, age less than 7 years, disease less than 4 years): Every 3 months
• Moderate risk (same but disease 4-7 years): Every 6 months
• Lower risk (older, ANA-, longer duration): Every 6-12 months

Screening Method: Slit-lamp examination by ophthalmologist (NOT visual acuity alone)

---

Viva Question 3: Systemic JIA and MAS

Q: "A 5-year-old with systemic JIA presents with persistent fever, confusion, and bruising. Blood tests show: platelets 80 (previously 400), ferritin 15,000, AST 200, fibrinogen 2.0 g/L. What is the likely diagnosis and how would you manage this?"

Model Answer:

Diagnosis: Macrophage Activation Syndrome (MAS) complicating systemic JIA

Rationale:

• Patient with systemic JIA developing new persistent fever (changed from quotidian pattern), CNS symptoms (confusion), bleeding (bruising)
• Laboratory features meet 2016 MAS Classification Criteria:
  • Ferritin > 684 ng/mL (15,000 is extremely high) ✓
  • "PLUS ≥2 of:"
    • Platelets ≤181 (80 is low, and falling from 400) ✓
    • AST > 48 (200 is elevated) ✓
    • Fibrinogen ≤360 mg/dL = 3.6 g/L (2.0 g/L is low) ✓

Management:

1. Emergency: ICU admission, multidisciplinary team (rheumatology, haematology, intensive care)

2. Investigations:

   • FBC, coagulation screen (PT, APTT, D-dimer)
   • LFTs, U&Es, triglycerides, LDH
   • Blood cultures (exclude sepsis)
   • Consider bone marrow aspirate (if diagnosis uncertain): haemophagocytosis (though NOT required for diagnosis)

3. Treatment:

   • High-dose IV methylprednisolone: 10-30 mg/kg/day for 3-5 days, then taper
   • Ciclosporin: 2-5 mg/kg/day (oral or IV) - reduces T-cell activation
   • Anakinra (IL-1 inhibition): May be effective; some centres use early
   • Supportive care: Transfusions (platelets, red cells), treat coagulopathy (fresh frozen plasma if bleeding), manage fever

4. Stop potential triggers: NSAIDs, recent methotrexate if just started

5. Monitor closely: Daily FBC, ferritin, LFTs, coagulation; watch for deterioration

6. Refractory MAS: Etoposide (chemotherapy agent used in HLH protocols) - reserved for severe, refractory cases

Prognosis: MAS has 8-10% mortality despite treatment; rapid recognition and aggressive management are critical.

---

Viva Question 4: Treatment Strategy for Polyarticular RF-Positive JIA

Q: "A 12-year-old girl presents with a 3-month history of symmetric polyarthritis affecting MCPs, PIPs, wrists, knees, and ankles. RF is positive on two occasions. X-rays show early erosions in MCPs. Outline your management plan."

Model Answer:

Diagnosis: Polyarticular RF-positive JIA (most severe JIA subtype; resembles adult RA)

Key Points:

• Aggressive, erosive disease: Requires early, intensive treatment
• RF-positive + erosions = poor prognostic factors
• Goal: Achieve inactive disease rapidly to prevent further joint damage

Management Plan:

1. Initial Assessment:

• Multidisciplinary team: Rheumatology, physiotherapy, occupational therapy, psychology
• Baseline investigations: FBC, LFTs, U&Es, ESR, CRP, ANA, anti-CCP, urinalysis
• Imaging: X-rays of hands/feet (baseline for monitoring); consider USS/MRI of most affected joints
• Ophthalmology: Uveitis screening (lower risk than oligoarticular but still required)
• Pre-treatment screening: Hepatitis B/C, HIV (if at-risk), TB (TST/IGRA + CXR), varicella serology

2. Pharmacological Treatment:

Immediate:

• NSAIDs: Naproxen 10-20 mg/kg/day for symptom relief
• Short course oral prednisolone: 0.5 mg/kg/day (maximum 20 mg) for 2-4 weeks as bridge therapy, then taper (while awaiting methotrexate effect)
• Intra-articular corticosteroids: For particularly active joints (e.g., knees, wrists)

First-line DMARD (start immediately):

• Methotrexate: 15 mg/m²/week subcutaneous (preferred over oral)
• Folic acid: 1 mg daily (or 5 mg once weekly, not on same day as methotrexate)

If Inadequate Response to Methotrexate (assess at 3-6 months):

• Add TNF inhibitor: Etanercept 0.8 mg/kg/week SC OR Adalimumab (weight-based dosing) every 2 weeks
• Continue methotrexate + biologic combination (synergistic effect)

If Inadequate Response to TNF Inhibitor:

• Switch to alternative biologic: Tocilizumab (IL-6 inhibitor), Abatacept (T-cell co-stimulation blocker), or alternative TNF inhibitor

3. Non-Pharmacological:

• Physiotherapy: Range of motion exercises, strengthening, low-impact aerobic exercise (swimming, cycling)
• Occupational therapy: Splinting (wrist splints for night use), joint protection strategies, adaptive devices
• School liaison: Ensure appropriate accommodations (extra time for tasks, modified PE, lift access if needed)

4. Monitoring:

• Disease activity: Clinical assessment (joint count, pain scores, function) every 3 months initially
• Methotrexate monitoring: FBC, LFTs every 2-4 weeks for first 3 months, then every 3 months
• Biologic monitoring (if started): FBC, LFTs every 3-6 months; annual TB screening (CXR)
• Growth: Height and weight at every visit
• Uveitis screening: As per risk stratification (likely 6-monthly)

5. Long-term:

• Aim for inactive disease (no active joints, normal inflammatory markers, no pain/stiffness)
• Once inactive disease achieved for 6-12 months: Consider cautious tapering of biologics/methotrexate (individualised, shared decision-making)
• Transition planning to adult rheumatology services from age 14 years onwards

Prognosis: With aggressive treatment, 50-70% achieve good control, but RF-positive polyarticular JIA has the highest risk of persistent, erosive disease into adulthood. Early treatment is critical.

---

13. Patient and Family Explanation

What is Juvenile Idiopathic Arthritis?

Juvenile Idiopathic Arthritis (JIA) is a condition where a child's joints become swollen, stiff, and painful. "Juvenile" means it affects children (under 16 years old), and "idiopathic" means we don't know the exact cause. It's the most common type of long-term joint condition in children.

JIA is not the same as arthritis in older adults. It's a separate condition that affects children and can behave very differently.

What Causes JIA?

We don't know exactly what causes JIA. It's thought to be a combination of:

• Genes (something a child is born with that makes them more likely to get JIA)
• The immune system (the body's defence system) getting confused and attacking the joints by mistake
• Possibly something in the environment (though we're not sure what)

Important: JIA is not caused by anything the parents or child did. It's not contagious (can't be caught from others).

Types of JIA

There are different types of JIA:

• Oligoarticular JIA: Affects 1-4 joints (usually knees, ankles). Most common type.
• Polyarticular JIA: Affects 5 or more joints (can be small and large joints).
• Systemic JIA (Still's disease): Causes high fevers, rash, and swollen lymph nodes, in addition to joint problems.
• Enthesitis-related arthritis: Affects joints and also the places where tendons attach to bones (often in the feet and lower back).
• Psoriatic arthritis: Arthritis along with a skin condition called psoriasis (scaly, red patches).

Your doctor will tell you which type your child has.

Symptoms of JIA

• Joint pain and swelling (especially knees, ankles, wrists, hands)
• Stiffness, especially in the morning or after sitting still
• Limping or not wanting to walk (in young children)
• Fever and rash (in systemic JIA)
• Fatigue (feeling tired)

Eye Problems (Uveitis)

Some children with JIA (especially those with oligoarticular JIA) can develop inflammation in the eyes called uveitis. This is serious because:

• It usually has no symptoms (child can't feel it)
• If not treated, it can damage vision permanently

This is why regular eye checks with an eye specialist (ophthalmologist) are very important - usually every 3-6 months, even if your child's eyes seem fine.

How is JIA Treated?

The good news is that treatments for JIA have improved a lot in recent years, and most children can live normal, active lives with the right treatment.

Medications:

1. Pain relievers and anti-inflammatories (NSAIDs like ibuprofen or naproxen): Help with pain and swelling
2. Joint injections (corticosteroids): Injected directly into swollen joints to reduce inflammation
3. Methotrexate: A medicine taken weekly (tablet or injection under the skin) that helps control inflammation and prevent joint damage
4. Biologic medicines (e.g., etanercept, adalimumab, tocilizumab): Advanced medicines given by injection that work very well to control JIA if methotrexate isn't enough

Physiotherapy and Exercise:

• Very important to keep joints moving and muscles strong
• Swimming and cycling are excellent
• Your physiotherapist will give you exercises to do at home

Occupational Therapy:

• Helps with daily activities and provides splints if needed

Side Effects of Medicines

All medicines can have side effects, but your doctor will monitor your child carefully:

• Methotrexate: Can cause nausea, tummy upset. Your child will have regular blood tests to check liver and blood counts. We give folic acid (a vitamin) to reduce side effects.
• Biologics: Can increase risk of infections. Make sure to tell your doctor if your child develops a fever or feels unwell. Keep vaccinations up to date (some vaccines need to be avoided during treatment).

What's the Outlook?

• With modern treatments, most children with JIA do very well
• 50-70% achieve remission (disease becomes inactive)
• Many children can eventually stop medicines and stay well
• The key is to:
  • Start treatment early
  • Take medicines as prescribed
  • Attend all appointments (doctor, physiotherapy, eye checks)
  • Keep joints moving with exercise

Living with JIA

• School: Your child can go to school. We can work with the school to make sure your child has support (e.g., extra time to get between classes, modified PE).
• Activities: Encourage your child to stay active. Swimming, cycling, and gentle sports are great. Avoid high-impact sports if joints are very swollen.
• Diet: No special diet is needed. A balanced, healthy diet is best.
• Support: Talk to your doctor about support groups - meeting other families with JIA can be very helpful.

When to Contact Your Doctor

Contact your doctor or rheumatology team if:

• Your child develops a high fever (especially if on biologics)
• Joint swelling gets much worse or new joints become swollen
• Your child seems very unwell
• Eye pain, redness, or vision changes (seek urgent medical attention)
• Any concerns about medicines or side effects

---

14. References

Primary Guidelines and Consensus Statements

1. Onel KB, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2022;74(4):521-537. PMID: 35233986

2. Fautrel B, et al. EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. Ann Rheum Dis. 2024;83(12):1636-1649. PMID: 39317417

Comprehensive Reviews and Epidemiology

3. Martini A, et al. Juvenile idiopathic arthritis. Nat Rev Dis Primers. 2022;8(1):5. PMID: 35087087

4. Barut K, et al. Juvenile Idiopathic Arthritis. Balkan Med J. 2017;34(2):90-101. PMID: 28418334

Classification

5. Petty RE, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-392. PMID: 14760812

6. Martini A, et al. Toward New Classification Criteria for Juvenile Idiopathic Arthritis: First Steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019;46(2):190-197. PMID: 30275259

Treatment: General and Non-Systemic JIA

7. Shenoi S, et al. Treatment of non-systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2024;20(3):145-157. PMID: 38321298

Systemic JIA

8. Hinze CH, et al. Treatment of systemic juvenile idiopathic arthritis. Nat Rev Rheumatol. 2023;19(12):776-788. PMID: 37923864

Macrophage Activation Syndrome

9. Ravelli A, et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68(3):566-576. PMID: 26314788

10. Grom AA. Genetics of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. Adv Exp Med Biol. 2024;1448:121-130. PMID: 39117811

Methotrexate

11. Ferrara G, et al. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting. Pediatr Rheumatol Online J. 2018;16(1):46. PMID: 29996864

12. Selvestrel D, et al. Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook. Expert Rev Clin Immunol. 2021;17(10):1117-1128. PMID: 34392756

13. Wibrand C, et al. Methotrexate Intolerance in Juvenile Idiopathic Arthritis: Definition, Risks, and Management. Paediatr Drugs. 2024;26(5):537-549. PMID: 39044097

Biologics

14. Ge L, et al. Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis. BMC Pediatr. 2025;25(1):212. PMID: 40148850

15. Strand V, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs. 2017;31(4):299-316. PMID: 28612180

16. Goettel AM, et al. Efficacy and Safety of Abatacept, Adalimumab, and Etanercept in Pediatric Patients With Juvenile Idiopathic Arthritis. J Pediatr Pharmacol Ther. 2021;26(2):157-168. PMID: 33603579

17. Verstegen RHJ, et al. Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. Arthritis Care Res (Hoboken). 2023;75(2):356-365. PMID: 35040593

Uveitis

18. Chang MH, et al. Uveitis in Children and Adolescents. Rheum Dis Clin North Am. 2021;47(4):619-635. PMID: 34635295

Recent High-Impact Studies

19. Brück N, et al. Juvenile idiopathic arthritis—Diagnosis and management. Z Rheumatol. 2025;84(3):196-203. PMID: 39961862

20. Küçükali B, et al. Evaluation of ILAR and PRINTO classifications for juvenile idiopathic arthritis: oligoarticular JIA vs early-onset ANA-positive JIA. Clin Rheumatol. 2025. PMID: 39883305

---